NASDAQ$PETS
PetMed Express · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
PetMed Express's Q1 2022 financial results were reviewed, revealing a decrease in sales compared to the prior year due to a unique situation with increased e-commerce demand and a competitive advertising market.
PetMed Express reported a decrease in sales by 17.6% to $79.3 million compared to the same quarter last year, with net income decreasing by 43% to $4.4 million, or $0.22 diluted per share. The decrease in sales was attributed to decreased new order and reorder sales. The company acquired approximately 92,000 new customers in the first fiscal quarter.
- Sales decreased by 17.6% to $79.3 million compared to the same period last year, but were relatively flat versus the quarter ended June 30th, 2019, prior to the pandemic.
- Reorder sales decreased by 11.8% to $70.9 million, while new order sales decreased 47% to $8.4 million.
- Net income decreased by 43% to $4.4 million, or $0.22 diluted per share.
- The company had $111.8 million in cash and cash equivalents and no debt as of June 30th, 2021.
Headline financials
Revenue & EPS history
PetMed Express · Revenue · Quarterly
$79.3M
Forward guidance
The company anticipates that advertising prices should revert back to more normal levels as the pandemic further subsides, which would increase the efficiency and effectiveness of our media spending, and thereby continue to help us gain new customers. The company expects many more of our reorder sales to eventually transition to AutoShip & Save by the end of our fiscal year.
Tailwinds
- Advertising prices should revert back to more normal levels as the pandemic further subsides, which would increase the efficiency and effectiveness of our media spending, and thereby continue to help us gain new customers.
- The company expects many more of our reorder sales to eventually transition to AutoShip & Save by the end of our fiscal year.
- There may be an opportunity to improve gross margins in the second half of fiscal year 2022, if the shift to prescription medications continue.
- The company will also continue investing in our e-commerce platform to better service our customers, by adding additional features to our Web site to further drive sales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-0.0%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
27 / 65 earnings
Positive
+40.8%
Q2 2020
Best reaction
-26.4%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -16.4% | -21.1% | — | |
| Q3 2026 | -3.6% | -8.7% | -15.5% | |
| Q4 2025 | +0.0% | -4.9% | -6.6% | |
| Q2 2026 | -1.4% | -2.7% | -8.2% | |
| Q1 2026 | -1.1% | -1.4% | -6.9% | |
| Q3 2025 | -14.8% | -20.1% | -22.7% | |
| Q2 2025 | +34.5% | +27.2% | +35.0% | |
| Q1 2025 | -11.0% | -13.0% | -4.5% | |
| Q4 2024 | -0.7% | -1.7% | -7.4% | |
| Q3 2024 | +0.2% | -1.2% | +8.9% | |
| Q2 2024 | -26.4% | -23.0% | -22.6% | |
| Q1 2024 | -2.8% | -6.4% | -20.0% | |
| Q4 2023 | +6.7% | +1.0% | -6.6% | |
| Q3 2023 | -11.1% | -13.3% | -19.6% | |
| Q2 2023 | -10.5% | -4.7% | -15.5% | |
| Q1 2023 | +4.3% | +4.2% | +0.9% | |
| Q4 2022 | +6.9% | +2.0% | +3.0% | |
| Q3 2022 | +7.2% | +7.7% | +3.4% | |
| Q2 2022 | +5.1% | +5.1% | +5.2% | |
| Q1 2022 | +7.1% | +13.0% | +3.2% | |
| Q4 2021 | +2.8% | +0.5% | +56.5% | |
| Q3 2021 | -14.3% | -11.1% | +3.2% | |
| Q2 2021 | -2.2% | -3.5% | -1.9% | |
| Q1 2021 | -16.0% | -23.8% | -17.4% | |
| Q4 2020 | +3.6% | -4.0% | -7.5% | |
| Q3 2020 | -11.0% | -11.2% | +4.0% | |
| Q2 2020 | +40.8% | +32.8% | +21.7% | |
| Q1 2020 | +2.5% | -1.5% | +5.1% | |
| Q4 2019 | -9.0% | -9.7% | -18.9% | |
| Q3 2019 | -6.2% | -3.4% | -3.1% | |
| Q2 2019 | +2.6% | +1.1% | -9.7% | |
| Q1 2019 | -13.0% | -11.8% | -6.4% | |
| Q4 2018 | -0.9% | +1.4% | +15.1% | |
| Q3 2018 | -4.8% | -10.2% | -12.0% | |
| Q2 2018 | +4.4% | -5.0% | +9.0% | |
| Q1 2018 | +18.6% | +19.3% | -10.7% | |
| Q4 2017 | +34.7% | +41.2% | +48.4% | |
| Q3 2017 | -5.1% | -5.4% | -3.6% | |
| Q2 2017 | -3.2% | -4.0% | +6.6% | |
| Q1 2017 | +6.0% | +5.8% | +3.3% | |
| Q4 2016 | +2.9% | — | — | |
| Q3 2016 | -4.8% | — | — | |
| Q2 2016 | +2.1% | — | — | |
| Q1 2016 | +0.5% | — | — | |
| Q4 2015 | +2.6% | — | — | |
| Q3 2015 | +14.3% | — | — | |
| Q2 2015 | -3.7% | — | — | |
| Q1 2015 | +5.0% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2014 | -12.0% | — | — | |
| Q2 2014 | -10.3% | — | — | |
| Q1 2014 | +12.7% | — | — | |
| Q4 2013 | -0.5% | — | — | |
| Q3 2013 | +7.0% | — | — | |
| Q2 2013 | +6.9% | — | — | |
| Q1 2013 | -16.3% | — | — | |
| Q4 2012 | -5.4% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2011 | -0.2% | — | — | |
| Q3 2012 | -0.2% | — | — | |
| Q2 2012 | -0.8% | — | — | |
| Q2 2011 | -0.8% | — | — | |
| Q1 2012 | -0.1% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q4 2011 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro